ClinicalTrials.gg
CompletedNCT00872885Updated Jul 15, 2021

Bunionectomy Trial With GRT6005

A Phase 2 interventional study of GRT6005 and Morphine in Post Operative Pain, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
113th of 1,098
258 · median 76
Started
2009
with 25 others
Phase 2
121 of 1,180
9 open now
Registered
79th of 1,180
by date

Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 113th largest by enrollment of the 1,098 interventional ones that give a count, is one of 26 that started in 2009, is one of 121 in phase 2, and was the 79th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,180 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The purpose of the trial is to determine whether the new centrally acting analgesic is effective in comparison to placebo and an active comparator (morphine).

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • analgesic
  • bunionectomy
  • surgery
  • post operative pain
  • single Hallux valgus repair
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects scheduled to undergo primary unilateral first metatarsal bunionectomy

Exclusion criteria

Exclusion Criteria:

  • to, or history of allergy or to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their .
  • Concomitant inflammatory disease.
  • Life-long history of seizure disorder or epilepsy.
  • Subjects with impaired renal function
  • Subjects with impaired hepatic function
  • Female subjects who are pregnant or breastfeeding.
  • Resting pulse rate is \<50bpm or >100 bpm after 5 minutes rest in supine position
  • resting blood pressure after 5 minutes rest in supine position: Systolic blood pressure is \<100mmHg or >140 mmHg Diastolic blood pressure is \<60 mmHg or > 90 mmHg
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    A

    Dose 1

    Drug: GRT6005

  • Experimental
    B

    Dose 2

    Drug: GRT6005

  • Experimental
    C

    Dose 3

    Drug: GRT6005

  • Active comparator
    D

    Morphine

    Drug: Morphine

  • Placebo comparator
    E

    Placebo

    Drug: Placebo

Interventions

  • liquid formulation, 200 to 600 µg, single dose, one day

    Also known as: Morphine

  • 60 mg

  • DrugPlacebo

    single dosage

06

What researchers measure

Primary outcomes

  1. Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments

    Time frame: 8 hours

Secondary outcomes

  1. Amount of rescue medication

    Time frame: 24 hours

  2. Adverse events

    Adverse Events reported by the participant as well as electrocardiogram, a measure of electrical activity of the heart and laboratory values

    Time frame: 24 hours

  3. Time to first rescue medication

    Time frame: 24 hours

  4. Patient Global Impression of Change

    Time frame: 24 hours

07

Study locations

1 site
  • Premier Research Group Ltd
    Austin, Texas 78705, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Aug 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2009
First posted
Mar 31, 2009
Start
Mar 2009
Primary completionActual
Aug 2009
CompletionActual
Oct 2009
Results delay requested
Jun 11, 2010
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00872885
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2009
Start date
Mar 2009
Primary completion
Aug 2009
Completion
Oct 2009
Last update
Jul 15, 2021

Study contacts

John Bothmer, Dr.
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion